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2ABSTRACT:
Protein biopharmaceuticals, among which interferon alpha-2b (IFNα-2b) that can be used 
in the treatment of chronic hepatitis C and hairy cell leukemia, have become an 
indispensable product of current medicine. However, their current high costs derived 
from the lack of cost-effective downstream strategies still limits their widespread use. 
Polymer-based aqueous two-phase systems (ATPS) or aqueous biphasic systems (ABS) 
can be used in biopharmaceuticals purification. This work investigates the application of 
ionic liquids (ILs) as adjuvants (at 5 wt%) in ATPS constituted by polyethylene glycol 
with a molecular weight of 600 g.mol-1 (PEG 600) and polypropylene glycol with a 
molecular weight of 400 g.mol-1 (PPG 400) at constant pH (8) to purify the recombinant 
protein IFNα-2b from Escherichia coli lysates. IFNα-2b was produced from isopropyl β-
d-1-thiogalactopyranoside (1 mM)-induced Escherichia coli BL21 (DE3) cultures and 
recovered from inclusion bodies after mechanical lysis, involving glass beads and a 
solubilization step with urea (8M) in alkaline pH (12.5). PEG-PPG-based ATPS 
involving ILs as adjuvants were subsequently applied for IFNα-2b purification, in which 
the target protein tends to migrate to the PEG-rich phase (being the phase also enriched 
in IL) and the remaining proteins tend to precipitate at the interface (fitting within the 
three-phase partitioning approach). In comparison with the ATPS without adjuvant, most 
systems comprising ILs as adjuvants lead to enhancements in the purification factors of 
IFNα-2b, namely from 2.28 ± 0.06 up to 6.77 ± 0.49. The purity of IFNα-2b is maximized 
using ILs composed of aromatic cations and anions with high hydrogen-bond basicity. 
The secondary structure of IFNα-2b is preserved during the purification step, as appraised 
by circular dichroism and western-blot studies. Overall, the obtained results demonstrate 
the ILs ability to tune the characteristics of the ATPS coexisting phases towards improved 
3purification processes, paving the way for their investigation in the purification of other 
high-value biological products.
41. INTRODUCTION:
The advent of biopharmaceuticals in modern medicine for the treatment of numerous 
diseases brought a significant impact on the improvement of global health. Proteins 
(including antibodies and/or other recombinant proteins) currently dominate the 
biopharmaceuticals market, with over 300 drug products approved and many more 
undergoing preclinical and clinical trials [1, 2], and with global sales reaching $100 
billion in 2017 [1]. Among these, interferon alpha-2b (INFα-2b) has become widely 
applied in the treatment of cancer, hepatitis, and hairy cell leukemia [3] , being marketed 
under the trademarks of Intron A® (Merck Sharp & Dohme), Rebetron® (Schering 
Plough) and distinct pegylated forms: PEG-Intron/Rebetol® (Schering Plough), Pegasys® 
(Roche/Genentech), PEG-intron® (Merck Sharp & Dohme) and ViraferonPeg® (Merck 
Sharp & Dohme) [1]. Owing to the wide spectrum of biological activities displayed by 
INFα-2b, namely in terms of antiproliferation, immunomodulation and antiviral 
properties [3], there has been an increased demand for the development of cost-effective 
manufacturing processes of recombinant human INFα-2b. 
The INFα-2b upstream phase has been typically accomplished through recombinant 
protein production in a host microorganism, such as Escherichia coli (E. coli) [4, 5]. 
Within the upstream stage, the major advantage of protein expression strategies in the 
form of inclusion bodies is that they can be produced in high concentrations, so that the 
amount of generated product often outweighs the additional downstream steps, which can 
boost time/space yields for recombinant protein production [6]. Although inclusion 
bodies have been seen as inactive protein aggregates, a new term of non-classical 
inclusion bodies has emerged in more recent years, which are believed to contain 
reasonable amounts of correctly folded protein, while exceeding 40% of total 
recombinant protein produced in cells [7, 8]. 
5The downstream processing of biopharmaceuticals comprises the removal of the 
process- and product-associated impurities, as well as other contaminants [9], allowing to 
obtain a purified protein sample. Currently, liquid chromatography is the key technique 
of most purification processes resorting to protein biopharmaceuticals [10], and has been 
applied to the purification of IFNα-2b comprising ion-exchange/size exclusion matrices 
[5, 11] or immobilized metal-affinity matrices/reverse-phase HPLC [12]. However, 
chromatography may present some limitations in terms of the high cost derived from the 
resin's low stability [13]. To overcome such limitations, alternative downstream processes 
have been investigated, including non-chromatographic operations, namely membrane-
based procedures [14], high-performance tangential flow filtration [15], high gradient 
magnetic fishing [16], precipitation [17], crystallization [17] and aqueous two-phase 
systems (ATPS) [18]. Initially proposed by Albertsson as a separation technique [19], 
ATPS are liquid-liquid systems formed when two aqueous solutions of two polymers, or 
a polymer and a salt, are mixed above given concentrations [20]. Some of the advantages 
displayed by ATPS include their biocompatibility, mostly due to the high-water content 
in both phases. Polymer-polymer and polymer-salt ATPS have been applied in the 
separation, recovery, and purification of several (bio)molecules, including antibiotics, 
proteins, DNA, and enzymes [21]. In particular, ATPS formed by PEG 8000 and the 
dibasic potassium phosphate salt were investigated for the purification of inclusion bodies 
resulting from the overexpression of external genes in prokaryotes [22]. Most polymer-
polymer-based ATPS investigated are composed of PEG and dextran [23-25]. However, 
due to the high cost of some dextran polymers, research has evolved towards the 
application of less expensive polymers, among which polypropylene glycol (PPG) [26]. 
In general, PEG and PPG present low toxicity and are approved by the Food and Drug 
6Administration (FDA), being both listed in the FDA’s Inactive Ingredient Guide for uses 
in topical, oral and other formulations [27, 28]. 
A common drawback associated to polymer-polymer-based ATPS is that they exhibit 
a small range of polarities between the two phases [20], thus hampering their effective 
application in the purification of target proteins from complex samples. To overcome 
such limitation, it has been proposed the functionalization of PEG with glutaric acid to 
improve the recovery yields of immunoglobulins [29, 30]. More recently, and with the 
same goal of improving the ATPS separation performance, ionic liquids (ILs) were 
proposed as adjuvants in polymer-salt ATPS [31-35]. This strategy has been successfully 
applied to increase the target proteins purification performance of PEG-citrate salt [31, 
33, 34], PEG-potassium phosphate [32], and PEG-ammonium sulphate [35] systems, 
although to the best of our knowledge was never attempted with polymer-polymer ATPS. 
Up to date, ATPS composed of alcohol/salt [36] and PEG/salt [37] were investigated for 
the purification of IFNα-2b.
In addition to ATPS, three-phase partitioning (TPP) approaches based on ammonium 
sulfate aqueous solutions and tert-butanol can be used to concentrate and purify proteins, 
involving the recovery of the target protein as a precipitate at the interface of the two 
liquid phases [38]. In particular, TPP has been used for the refolding of proteins from 
urea-solubilized inclusion bodies [39]. However, TPP based on ATPS can be applied as 
well for the purification of target proteins by inducing their precipitation at the ATPS 
interface, while avoiding the use of tert-butanol. Recently, IL-based TPP have been 
proposed by Alvarez et al [40, 41] to recover model food proteins at the ATPS interface. 
Herein it is described the production and purification of IFNα-2b from E. coli BL21 
(DE3) inclusion bodies using PEG -600-PPG-400-based ATPS/TPP with ILs as adjuvants 
(at 5 wt%). Previous reports [31-35] investigated the use of ILs as adjuvants in polymer-
7salt systems, which are composed of salts presenting a high salting-out ability and a high 
ionic strength [42]. Distinctly, the current work focuses on two polymers as phase-
forming components, thus providing a low ionic strength, and hence a more amenable 
environment to address the relevance of the ILs chemical structure to tailor the phases 
characteristics, which is beneficial when envisioning the purification of a target protein 
from a complex medium rich in other proteins. The ATPS process was combined with 
TPP, in which the purification of the target protein was aimed at the PEG-rich phase with 
the simultaneous precipitation of the remaining proteins at the ATPS interface. 
2. EXPERIMENTAL SECTION:
2.1. Materials, strain, and media:
The plasmid pET-3a containing a codon-optimized version of the gene coding for 
human IFNα-2b (NCBI accession KY780371.1, full nucleotide sequence given in the 
Supplementary Information) – pET-3a_IFNα-2b – was acquired from Genscript 
(Piscataway, New Jersey, USA) and used for the heat-shock transformation of E. coli 
BL21 (DE3) chemically competent cells (Merck/Sigma-Aldrich, St. Louis, USA). The 
reagents used in the preparation of E. coli culture media, including tryptone and yeast 
extract, were acquired from Biokar Diagnostics (Cedex, France), while agar and NaCl 
(purity >99.5%) were bought from PanReac (Barcelona, Spain). The salts MgCl2 (purity 
>99%) and MgSO4 (purity >99%) were obtained from Prolab (São Paulo, Brazil). 
Reagents required for bacterial fermentation, cell lysis and protein recovery, such as 
isopropyl β-d-1-thiogalactopyranoside (IPTG), ampicillin sodium salt, and 
phenylmethylsulfonyl fluoride (PMSF), were provided by NZYtech (Lisbon, Portugal), 
Pierce protease inhibitor was obtained from Fisher Scientific (Massachusetts, USA) and 
Triton X-100, urea (purity 99%) and 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris) 
8were acquired from Acros Organics (New Jersey, USA). Polymers used as ATPS phase-
forming components were purchased from Alfa Aesar, Massachusetts, USA (PEG 600) 
and Merck/Sigma-Aldrich, St. Louis, USA (PPG 400). The list of names, acronyms, 
chemical structures, purities and suppliers of the ILs investigated as adjuvants in this work 
as well as of the polymers used in ATPS are shown in Table 1. 
Reducing sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels were stained with BlueSafe from NZYtech (Lisbon, Portugal). Total protein 
quantification was performed using the Pierce BCA protein assay from Thermo Fisher 
Scientific (Massachusetts, USA), while the quantification of IFNα-2b in ATPS phases 
was achieved with the human IFN-α pan ELISAPRO kit (MabTech, Stockholm, Sweden - 
Fig. S1 in Supplementary Information). The IFNα-2b standard (Recombinant human 
Interferon alpha-2b protein) and the Anti-IFNα-2b antibody were acquired from Abcam 
(Cambridge, United Kingdom), while the secondary antibody Anti-Chicken IgY (IgG) 
was obtained from Sigma-Aldrich (St. Louis, USA).
2.2. Biosynthesis and recovery of IFNα-2b:
Recombinant production of IFNα-2b was performed based on the protocol 
described by Ling and co-workers [36], yet with minor modifications: E. coli BL21 (DE3) 
was cultivated in shake-flasks containing SOB medium, and induction was performed 
with 1 mM IPTG when the optical density (600 nm) reached 0.2. Cell lysis was performed 
using glass beads according to the protocol previously reported by Passarinha and co-
workers [43], while the subsequent recovery of IFNα-2b from inclusion bodies was 
achieved using a buffer containing urea in an alkaline pH, based on the works developed 
by Prazeres [4] and Mukherjee [5] research groups and general guidelines provided by 
Palmer and Wingfield [44]. Additional details on the recombinant production and 
recovery of IFNα-2b are given in the Supplementary Information.
92.3. Phase Diagrams:
The phase diagrams of ATPS composed of PEG 600 + PPG 400 + 10 mM Tris 
pH 8 were determined in presence of 5 wt% of the following ILs: [C2mim]Cl, [C4mim]Cl, 
[C6mim]Cl, [C4mim]Br, [C4mim][CH3COO], [N4444]Cl, and [Ch]Cl - cf. Fig. 1. Each 
ATPS binodal curve was determined by the cloud point titration method at 25 (± 1) °C 
and atmospheric pressure, as previously described [45]. For the determination of the 
liquid-liquid phase diagrams with ILs as adjuvants, 10 mM Tris (pH 8) aqueous solutions 
and buffered solutions of PEG 600 and PPG 400 containing 5 wt% of the respective IL 
were used, allowing to keep the IL concentration constant along all the phase diagram 
regions. Buffered solutions (10 mM Tris pH 8) of PEG were drop-wise added to buffered 
solutions of PPG until a cloudy biphasic solution was obtained; subsequently, drop-wise 
addition of water proceeded until a monophasic region was observed. This procedure was 
carried out under constant stirring and the system's composition was determined by 
weight (±10-4 g). The experimental binodal curves were fitted using equation 1:[PEG] = Aexp[(B[PPG]0.5) ― (C[PPG]3)]   (Eq.1)
where [PEG] and [PPG] represent the weight percentage (wt%) of each polymer, and A, 
B and C are fitting parameters obtained by regression of the experimental data. 
2.4. Purification of IFNα-2b in polymer-polymer aqueous two-phase systems:
The purification of IFNα-2b in PEG-PPG-based ATPS was evaluated in a 
common mixture point (30 wt% of PEG 600 + 30 wt% of PPG 400 + 5 wt% of IL). After 
careful weighing each ATPS component (including IL if present), systems were 
homogenized, 22.5 wt% of dialyzed inclusion body fraction was added (corresponding to 
a total protein mass of ca. 400 µg), and 10 mM Tris (pH 8) was added to make up 100 
wt%. Subsequently, the mixture was stirred for 5 min at room temperature (25 (± 1) °C) 
and was then centrifuged (3500 rpm for 2 min at room temperature) to enhance phase 
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separation. Phases (PEG-rich bottom and PPG-rich top phases) were isolated using a 
syringe and their weight determined. The precipitate was also isolated and dissolved in 
10 mM Tris (pH 8). Both phases and the dissolved precipitate were analyzed for total 
proteins and IFNα-2b contents. Total protein concentration was determined by the Pierce 
BCA protein assay using convenient dilutions of ATPS phases, yielding typically 
concentrations below 3 wt% of each polymer that avoid polymer interferences in the 
determination of the proteins content, in agreement with the recommendations of Beutel 
and co-workers [46]. The migration pattern of IFNα-2b and remaining proteins between 
the two phases and precipitation at the interface were evaluated by SDS-PAGE; 
additionally, the levels of IFNα-2b were quantified by enzyme-linked immunosorbent 
assay (ELISA) (additional details are given in the Supplementary Information). Using the 
values obtained for the concentration of IFNα-2b and/or total proteins in each phase and 
at the precipitate, both the purification factor and extraction efficiency were calculated to 
evaluate the purification performance of the studied systems. 
The overall purification performance of the ATPS was evaluated through the 
determination of the purification factor (PF) and equation 2:
 (Eq. 2)PFIFNα ― 2b = ([IFNα - 2b]PEG ― rich phase ÷ [Total proteins]PEG ― rich phase)([IFNα - 2b]initial sample ÷ [Total proteins]initial sample)
where [IFNα-2b] represents the concentration of IFNα-2b (µg/ml) in the PEG-rich phase 
and in the initial solubilized sample, and [total proteins] represents the concentration of 
total proteins (including IFNα-2b) in the PEG-rich phase and initial solubilized sample. 
Finally, IFNα-2b extraction efficiencies (EE) were calculated using equation 3:
EE (%) =  𝑤 IFNα - 2bPEG(w IFNα - 2bPEG + w IFNα - 2bPP + w IFNα - 2bPPG) × 100 (Eq.3)
where w IFNα-2b represents the weight of IFNα-2b (µg) in the PEG-rich phase (PEG), 
PPG-rich phase (PPG) and the resulting precipitate (PP) of each ATPS.
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The migration pattern or precipitation of total proteins in each sample was 
analyzed by SDS-PAGE according to the method of Laemmli [47]. To remove 
interferences caused by polymers and/or ILs, samples were precipitated using acetone 
(1:4 (v/v)) and the mixture was incubated at -20 °C overnight, followed by centrifugation 
at 13000 rpm (4 °C for 15 min) [48]. The resulting pellet from each ATPS phase was then 
dissolved in 50 µL of 10 mM Tris pH 8. The precipitates at the ATPS interface were 
recovered and dissolved in 100 µL of 10 mM Tris pH 8. Samples were diluted 1:1 in 
Laemmli loading buffer (4% (w/v) of SDS, 20% (w/v) of glycerol, 120 mM of Tris-HCl 
pH 6.8, 0.02% (w/v) bromophenol blue) and denatured by incubation at 95 °C for 5 min, 
and were then injected in the polyacrylamide gel. Lastly, protein staining was achieved 
by incubation with BlueSafe under mild agitation for 1 h. 
Western blot was performed to identify immunologically active IFNα-2b. To this 
end, proteins were transferred from an unstained SDS-PAGE gel (obtained as described 
above) to a nitrocellulose membrane (Bio-Rad, Hercules, USA) over 30 min at 200 mA 
and 4 °C in a specific buffer [50 mM Tris, 380 mM glycine and 20% (v/v) methanol]. 
Membranes were blocked with TBS-T (pH 7.4) supplemented with 5% (v/v) non-fat milk 
during 1 h at room temperature and were then probed with primary antibodies recognizing 
human IFN-α2b [1:2000 in TBS-T and 0.5% (w/v) non-fat milk] overnight at 4 °C. After 
three consecutive washes with TBS-T, membranes were incubated with HRP-labeled 
anti-chicken/rabbit IgG secondary antibody diluted 1:10000 in TBS-T containing 5% 
(w/v) non-fat milk. Signal detection was performed with ECL substrate (Advansta Inc., 
CA, USA) according to the manufacturer’s instructions, and images were acquired with 
the ChemiDocTM XRS system (Bio-Rad, Hercules, USA) and analyzed with Image Lab 
(Bio-Rad, Hercules, USA).
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Circular dichroism (CD) was used to address the secondary structure of IFNα-2b 
and to infer possible changes induced during the ATPS purification step. Analyses were 
performed in a JASCO J-815 spectropolarimeter (JASCO, Easton, MD, USA). To remove 
interferences caused by polymers and/or ILs, the target ATPS phase was subjected to 
dialysis against PBS buffer (Sigma Aldrich, Missouri, USA). CD spectra were recorded 
at 25 °C in the interval of 195-280 nm in quartz Suprasil CD cuvettes (0.1 cm), using the 
following acquisition parameters: data pitch, 0.5 nm; bandwidth, 1.0 nm; response, 4 s; 
and scanning speed, 50 nm/min. 
2.5. Partition coefficients of ionic liquids:
The partition coefficients of each IL (KIL) in ATPS were determined to evaluate 
their influence on the IFNα-2b partitioning between the two phases following the protocol 
previously reported by Coutinho and co-workers [45]. To accomplish this, ATPS were 
prepared with the following composition: 30 wt% of PEG 600, 30 wt% of PPG 400, 35 
wt% of an aqueous solution with 10 mM Tris pH 8 and 5 wt% of IL. The mixture point 
herein selected for the determination of KIL was the same from that employed in the 
purification experiments of IFNα-2b, allowing to infer if the partition of IFNα-2b is 
governed by the quantity of IL present in each ATPS phase. The concentration of the 
chloride-based ILs in each phase was determined using a Metrohm 904 Titrando ion 
chloride electrode. A stock solution of NaCl 0.2 M was prepared and diluted in 
concentrations ranging from 0.1 to 100 mM to establish a calibration curve. A total ionic 
strength adjustment buffer (TISAB) composed of NaNO3 2 M was added to all standard 
solutions and samples to keep the ionic strength. Each ATPS phase was diluted 250 times 
before analysis, guaranteeing that ILs are dissociated in aqueous media. The partition 
coefficient (KIL) of each IL was determined using equation 4: 
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 (Eq. 4)𝐾IL =  [IL] PPG[IL] PEG
where [IL]PPG and [IL]PEG represent, respectively, the concentrations (M) of each IL in 
the top and bottom phases. Top and bottom phases correspond, respectively, to the PPG- 
and PEG-rich phases in all investigated systems. The KIL values result from the average 
of two independent measurements with the respective standard deviations.
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Table 1 - List of names, acronyms, chemical structures and suppliers of ILs and polymers investigated in this work.
Polymers
Name/Acronym Polyethylene glycol (PEG) 600 Polypropylene glycol (PPG) 400
Chemical 
Structure
Supplier Alfa Aesar
(Massachusetts, USA)
Merck/Sigma-Aldrich
(St. Louis, Missouri, USA)
Imidazolium-based ILs
Name/Acronym [C2mim]Cl
1-Ethyl-3-methylimidazolium chloride
[C4mim]Cl
1-Butyl-3-methylimidazolium chloride
[C4mim]Br
1-Butyl-3-methylimidazolium bromide
[C4mim][CH3COO]
1-Butyl-3-methylimidazolium acetate
[C6mim]Cl
1-Hexyl-3-methylimidazolium chloride
Chemical 
Structure
Purity (wt%) 98 99 98 97 98
Supplier Iolitec®
(Ionic Liquid Technologies, Germany)
Iolitec®
(Ionic Liquid Technologies, Germany)
Iolitec®
(Ionic Liquid Technologies, Germany)
Iolitec®
(Ionic Liquid Technologies, Germany)
Iolitec®
(Ionic Liquid Technologies, Germany)
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Cholinium-based IL Ammonium-based IL Pyrrolidinium-based IL Piperidinium-based IL
Name/Acronym [Ch]Cl
Cholinium chloride
[N
4444
]Cl
Tetrabutylammonium chloride
[C4mpyr]Cl
1-Butyl-1-methylpyrrolidinium chloride
[C4mpip]Cl
1-Butyl-1-methylpiperidinium chloride
Chemical 
Structure
Purity (wt%) 98 98 99 99
Supplier Acros Organics
(New Jersey, USA)
Merck/Sigma-Aldrich
(St. Louis, Missouri, USA)
Iolitec®
(Ionic Liquid Technologies, Germany)
Iolitec®
(Ionic Liquid Technologies, Germany)
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3. RESULTS AND DISCUSSION:
3.1. Production and recovery of IFNα-2b:
The purification of IFNα-2b from recombinant bacterial lysates is herein 
addressed due to this protein potential as a major biopharmaceutical currently employed 
in the treatment of several human diseases [1]. Considering that E. coli continues to be a 
major host for manufacturing biopharmaceutical proteins [1], and the high product titers 
delivered by E. coli inclusion bodies [7], it is of utmost importance to develop protein 
purification strategies from inclusion bodies.
The manufacture of IFNα-2b is commonly performed using E. coli, for which 
distinct operational parameters such as medium composition, inducer concentration and 
period of induction influencing the production of IFNα-2b should be initially optimized. 
After testing different culture media, it was observed that the production of monomeric 
IFNα-2b was maximized using the SOB medium, mainly in the form of inclusion bodies 
at 37 °C and 250 rpm. The time growth profile of IFNα-2b in the SOB medium was 
evaluated by SDS-PAGE (Fig. S2 in the Supplementary Information), whereas the 
densitometric analysis of the band corresponding to the target protein (molecular weight 
of approximately 19 kDa) revealed that higher IFNα-2b levels are achieved after 3 h of 
induction. Accordingly, the production of IFNα-2b was then performed in SOB medium 
with 1 mM IPTG and the induction carried out during 3 h, conditions that were kept 
constant in all further investigations. 
Fractionation of recombinant E. coli into soluble and insoluble fractions after lysis 
with glass beads showed that IFNα-2b preferentially accumulates as inclusion bodies; this 
profile is not significantly changed using distinct concentrations of inducer or 
temperatures (data not shown). The preferential accumulation of IFNα-2b as inclusion 
bodies in E. coli-based systems is in good agreement with previous reports [4, 5] and 
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requires additional processing steps envisaging the isolation and solubilization of the 
target protein. Considering the works developed by Prazeres [4] and Mukherjee [5] 
research groups on the solubilization of IFNα-2b from inclusion bodies, and general 
guidelines provided by Palmer and Wingfield [44], an optimized strategy towards the 
efficient solubilization of IFNα-2b was here adopted. The designed protocol includes two 
sequential steps with 1% (v/v) Triton X-100 and 4 M urea (in 10 mM Tris, pH 8), followed 
by solubilization with 8 M urea pH 12.5. Each of these fractions was subsequently 
analysed by SDS-PAGE and western blot to evaluate if there are losses of the target 
protein in the washing steps and if IFNα-2b is efficiently solubilized. These results are 
shown in Fig. 2. Some protein impurities are removed in the designed washing steps, but 
no losses of IFNα-2b occur. Moreover, immunologically active IFNα-2b was identified 
in the fraction solubilized with the alkaline urea buffer, with a molecular weight of 
approximately 19 kDa.
Based on the obtained results, the production of IFNα-2b was set up in the 
following conditions: E. coli cultivation at 37 °C and 250 rpm in shake-flasks containing 
SOB medium using 1 mM IPTG, and an induction period of 3 h. The inclusion body 
fraction was solubilized with 8 M urea in an alkaline buffer, which was subsequently 
dialyzed to remove urea against Tris buffer pH 8, constituting this sample the one used in 
ATPS.
3.2. ATPS phase diagrams:
To use ATPS as an extraction/purification strategy it is of utmost importance to 
define their monophasic and biphasic regions by the determination of the respective phase 
diagrams. Considering that the addition of ILs as adjuvants in ATPS can influence not 
only the partition of proteins but also the extent of the biphasic region, the binodal curves 
for quaternary (PEG 600 + PPG 400 + 10mM Tris pH 8 + 5 wt% IL) and ternary (same 
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phase-forming components but without IL) systems were first determined at 25 (± 1) °C 
and atmospheric pressure. The respective phase diagrams in an orthogonal representation 
are shown in Fig. 1. Detailed experimental data and the corresponding regression 
parameters obtained by Eq. (1) are reported in Table S1 in the Supplementary 
Information. 
All mixture compositions above each binodal curve shown in Fig. 1 result in the formation 
of a biphasic regime, in which the closest to the axes the curve is, the lower the amount 
of phase-forming components required for two-phase formation. The ability of ILs as 
adjuvants to induce the formation of two-phase systems follows the trend: [Ch]Cl > 
[C2mim]Cl ≈ [C4mim][CH3COO] > [C6mim]Cl ≈ [C4mim]Cl > [C4mim]Br > [N4444]Cl > 
No IL adjuvant. Overall, the presence of all ILs increase the two-phase formation ability. 
The predicted ILs hydrogen bond acidity (α) of [N4444]Cl, [C4mim]Cl and [Ch]Cl are, 
respectively, 0.423, 0.986 and 1.555 [45, 49, 50], which are grouped in increasing order 
of hydrophilicity. According to the data shown in Fig. 1A, there is a good correlation 
between the ability of each IL cation to donate protons and to establish hydrogen-bonds 
and their ability to induce the formation of two phases. On the other hand, the predicted 
hydrogen-bond basicity (β) of [C4mim+]-based ILs paired with bromide, chloride, and 
acetate anions are, respectively, 0.87, 0.95 and 1.20 [50]. By being the most hydrophilic 
IL, the acetate-based IL is the one with the highest impact in the formation of two phases. 
As verified with the IL cation effect, the higher the ability of the IL anion to accept protons 
and establish hydrogen-bonds, the higher the IL salting-out ability and capacity to create 
two-phase systems (Fig. 1B). Although with a different anion, the predicted hydrogen 
bond acidity (α) of bis(trifluoromethylsulfonyl)imide-([NTf2]-)-based ILs paired with 1-
ethyl-3-methylimidazolium-, 1-butyl-3-methylimidazolium- and 1-hexyl-3-
methylimidazolium-cations was reported to be, respectively, 0.750, 0.692 and 0.659 [49], 
19
allowing to address the IL cation effect to donate protons. As discussed above, also when 
analysing the IL cation alkyl side chain length, there is a common trend between the IL 
cation hydrogen-bond acidity and ability to create ABS (Fig. 1C).
Based on the exposed, the effect of ILs on the PEG-PPG-water binodal curves follows 
the IL ions capacity to accept or donate protons (measured as a function of α and β values), 
and thus to establish hydrogen-bonds, which may occur with water or the –OH terminal 
groups of both polymers. An increase of the ILs’ capacity to accept or donate protons also 
correlates with the ILs partitioning to the PEG-rich phase, the phase where ILs are 
preferentially enriched (data given in the Fig. S3 in Supplementary Information). As a 
consequence, the differences in hydrophobicity of both ATPS phases are enhanced by 
using ILs with higher hydrogen-bond donor and acceptor characteristics, resulting in 
increased phase separation of the PEG-PPG systems herein investigated. 
Previously, it was reported that ILs are preferentially partitioned towards the PEG-rich 
phase when applied as adjuvants in PEG 600-Na2SO4 [51] and PEG 400-(NH4)2SO4 
ATPS [45], the most hydrophobic phase in such systems. In these reports, an increase of 
the ILs’ hydrophobic nature leads to a lower affinity for water, thus enhancing phase 
separation [45, 51]. The results obtained in this work are in good agreement with previous 
reports since ILs preferentially partition to the PEG-rich phase, and the higher the 
partition extent the higher is the phase separation ability. However, in the current work, 
the PEG-rich phase is the most hydrophilic (when compared to the PPG-rich phase and 
not with a salt-rich phase as shown in the literature [45, 51]), and the opposite was 
observed. ILs with a higher hydrophilic nature, reflected by higher hydrogen-bond 
basicity and hydrogen-bond acidity values, are those that lead to an easier phase 
separation, i.e. requiring lower amounts of phase-forming components (PEG and PPG) to 
create ATPS.
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The feasibility of PPG 400 and PEG 600 to form ATPS with some ILs used in this work 
was previously investigated [52-55]. Such studies demonstrated that more hydrophobic 
ILs such as [N4444]Cl or [C6mim]Cl present a low capability to dehydrate moderately 
hydrophobic polymers such as PPG 400, and hence no ATPS could be obtained using 
such ILs and PPG 400. Moreover, and although [C4mim]Cl, [C4mim]Br, and 
[C4mim][CH3COO] are able to form ATPS with PPG 400, no ATPS are formed at the 
concentrations applied in the current work (5 wt%) [55]. With respect to PEG and at the 
concentrations of ILs applied in this work (5 wt%), a monophasic region will be obtained 
with PEG 1000-[C4mim]Cl [52], PEG 1500-[C2mim]Cl [53], and PEG 600-[Ch]Cl [54]. 
It has been additionally shown that PEGs with a molecular weight lower than 3400 g 
mol-1 are not able to form two-phases at 25 °C with protic ILs [56]. Overall, the results 
and trends reported in the literature point out that at the concentrations of ILs applied (5 
wt%) in the current work, such compounds will not form two-phases with PPG 400 or 
PEG 600.
3.3. IFNα-2b purification using polymer-polymer aqueous two-phase systems 
using ILs as adjuvants:
PEG and PPG were investigated as phase-forming components of ATPS aiming 
the purification of IFNα-2b from E. coli inclusion bodies. The biocompatible behaviour 
displayed by such polymers coupled with their low molecular weight (600 and 400 g mol-
1, respectively for PEG and PPG) allows to have relatively low viscous phases. On the 
other hand, the use of ILs as adjuvants in polymer-polymer ATPS represents a more 
amenable environment in which the effect of the ILs is less masked by salting-out effects 
occurring in the previously studied salt-polymer-based ATPS [31-35].
The purification of IFNα-2b was investigated using a common mixture point in 
ATPS: PEG 600 at 30 wt% + PPG at 30 wt% + IL at 5 wt%. In general, an interfacial 
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precipitate corresponding to precipitated proteins was formed in all systems (Fig. S4 in 
the Supplementary Information), fitting within the three-phase partitioning approach 
previously applied for the purification of proteins [57] and antibodies [58]. Contrarily to 
these reports, the interfacial precipitate in the current work is not preferentially enriched 
in the target protein, but instead in the remaining proteins. 
The migration patterns and precipitation of the target protein and protein 
impurities were evaluated by SDS-PAGE, whose results are shown in Fig. 3 and Figs. S4 
and S5 in the Supplementary information. In general, no proteins are found in the top 
PPG-rich phase, which is the most hydrophobic ATPS phase. Instead, both IFNα-2b and 
protein impurities preferentially migrate to the bottom PEG-rich phase or precipitate at 
the interface, in which the latter is most enriched in protein impurities. The SDS-PAGE 
profile of the initial sample (Fig. 3) shows that IFNα-2b appears as a 19 kDa band (identity 
confirmed by western-blot in Fig. 2). Moreover, multiple bands with higher molecular 
weights corresponding to E. coli endogenous proteins demonstrate the evident complexity 
of the starting sample and the inherent difficulty to separate IFNα-2b from proteins with 
similar properties. 
Without the addition of an adjuvant, IFNα-2b migrates to the PEG-rich phase (Fig. 
3), although some target protein precipitates at the interface (Fig. S4 in the Supplementary 
Information). When ILs are added as adjuvants, it is seen that more hydrophobic and 
higher volume ILs, such as [N4444]Cl, lead to a lower recovery yield of IFNα-2b in the 
bottom phase (Fig. 3). However, good recoveries of IFNα-2b in the PEG-rich phase were 
observed using the investigated imidazolium-, ammonium-, piperidinium-, and 
pyrrolidinium-based ILs, outperforming the system without the addition of adjuvant (Fig. 
3). Overall and in all systems, the PEG-rich phase was identified as the ATPS phase 
promoting the highest recoveries of IFNα-2b in a more purified form. 
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The SDS-PAGE analysis carried out provided useful insights about the 
purification performance of the investigated PEG-PPG systems. However, the need of an 
acetone precipitation step and subsequent dissolution in a specific buffer may not 
guarantee that all proteins are equally precipitated, hence preventing an accurate 
evaluation of the proteins partition behavior and precipitation. Therefore, ELISA was 
used to quantify the levels of biologically active IFNα-2b in each ATPS phase and BCA 
was used to determine the total proteins content in all samples. Based on these assays, the 
IFNα-2b purification factors and extraction efficiencies in the PEG-rich phase were 
determined, allowing to evaluate the purification performance of ATPS with distinct ILs 
as adjuvants. The overall performance of PEG-PPG ATPS towards the purification of 
IFNα-2b is shown in Fig. 4, being represented the purification factors and extraction 
efficiencies of the target protein in the bottom (PEG-rich) phase. In general, good 
extraction efficiencies (EE, %) towards the PEG-rich phase were obtained ranging from 
87% (for the ATPS constituted by [N4444]Cl) to 95% (for the ATPS composed of 
[C4mim]Cl or [Ch]Cl), indicating that the majority of IFNα-2b is present in the PEG-rich 
phase.
The obtained results show that the addition of adjuvants significantly improves 
the purity of IFNα-2b recovered in the bottom phase, which is mainly due to the selective 
precipitation of the remaining proteins at the ATPS interface. Furthermore, the trend in 
increased purification performance closely follows the ILs enrichment in the PEG-rich 
phase (cf. Fig. S3 in the Supplementary Information with the partition coefficients of 
chloride-based ILs). In summary, the higher the IL content in the PEG-rich phase, the 
higher the purification factor obtained for IFNα-2b. Overall, ILs composed of an aromatic 
cation, such as imidazolium-based, are those that lead to a higher separation performance, 
i.e. by inducing the selective precipitation of the remaining proteins at the interface. On 
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the other hand, higher purification factors are obtained with ILs containing ethyl and butyl 
side chains at the imidazolium cation, indicating that an increase in the alkyl side chain 
length of the IL cation slightly decreases the IFNα-2b purification factor (Fig. 4). Finally, 
ILs containing anions with higher hydrogen-bond basicity, namely [C4mim][CH3COO] 
and [C4mim]Cl, are those that lead to higher purification factors. As shown in Fig. 4, the 
application of 5 wt% of [C4mim][CH3COO] as an adjuvant in PEG-PPG ATPS leads to 
the highest purification factor obtained, representing an increase by a factor of 7 over the 
initial sample, and allowing an improvement of the purification factor of 3.5 in 
comparison with the system without IL as adjuvant. These results clearly support the ILs 
designer solvents aptitude and capacity to tailor the phase’s polarities and characteristics 
aiming at improving the separation of proteins from biological media. 
Given the best results obtained with [C4mim][CH3COO] as an adjuvant at 5 wt% 
in PEG-PPG ATPS, distinct concentrations (2.5 and 12.5 wt%) of this IL were further 
evaluated. However, no improvements in the purification factors were accomplished (Fig. 
S6 in the Supplementary Information). Accordingly, in addition to the quantity of IL in 
the bottom phase which seems to play a relevant effect as appraised by the IL partition 
coefficients discussed above, the chemical structure of each IL seems to play a more 
significant role to improve the studied ATPS separation performance. 
All ILs have a positive charge center, allowing the establishment of electrostatic 
interactions with the target protein, which is negatively charged at pH (8) (IFNα-2b pI = 
5.9 [5]). Although it has been reported that NaCl increases the purification factor of IFNα-
2b in alcohol-salt [36] and polymer-salt [37] ATPS, it should be remarked that ILs 
additionally allow a range of non-covalent interactions to be established with the target 
protein, including electrostatic, hydrophobic, π-π, cation-π, and hydrogen-bonding 
interactions that can be exploited towards the development of enhanced IFNα-2b 
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purification processes. Taking into account the results obtained and ILs chemical 
structures, and in addition to electrostatic interactions common to all ILs, the enrichment 
of IFNα-2b in the PEG-phase containing ILs as adjuvants seems to be driven by aromatic 
interactions between the aromatic residues of IFNα-2b and aromatic IL cations and 
hydrogen bonding interactions established between IL anions and IFNα-2b. 
3.4. Stability of purified IFNα-2b:
Western blot analysis of each phase of representative ATPS in the absence and 
presence of 5 wt% of [C4mim][CH3COO] allowed the identification of a single band with 
a molecular weight of approximately 19 KDa (Fig. 5), corresponding to immunologically 
active IFNα-2b, being in good agreement with the IFNα-2b standard. Moreover, no 
dimers of the target protein were detected, indicating that with the purification strategy 
herein optimized, no protein aggregation was observed. Concerning the PPG-rich phases 
of both ATPS, no IFNα-2b was detected, as with the SDS-PAGE profiles of these phases 
(Fig. S5 in the Supplementary Information). On the other hand, IFNα-2b was detected in 
the precipitates of both systems, indicating that some losses of the target protein occur in 
the precipitate, in agreement with the SDS-PAGE profile (Fig. S4 in the Supplementary 
Information). 
Circular dichroism (CD) spectroscopy was used to infer if the purification process 
impacts the secondary structure of the target protein by comparison with a commercial 
IFNα-2b standard. The CD spectra of the bottom phase (dialyzed against PBS) isolated 
from an ATPS composed of 30 wt% PEG 600, 30 wt% PPG 400 and 5 wt% [C4mim]Cl 
and that of the standard are shown in Fig. S7 in the Supplementary Information. 
Considering the CD spectra of IFNα-2b previously reported in the literature [59] and of 
the protein standard, two minimum ellipticity peaks are observed at 208 and 222 nm, 
which are typical of alpha-helix proteins as is the case of IFNα-2b. In general, no major 
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differences were obtained between the dialyzed bottom phase of the ATPS investigated 
and the IFNα-2b standard, indicating that the secondary structure of the target 
recombinant protein is not significantly changed and remains stable during the ATPS/TPP 
purification step. 
Although previous reports have shown that imidazolium-based ILs could 
destabilize and/or impair the biological activity of enzymes and proteins [60, 61], the 
imidazolium-based ILs herein investigated, at least when used as adjuvants at 5 wt% in 
PEG-PPG ATPS, do not lead to losses of stability of the target protein. Unlike the 
application of ILs as phase-forming components in polymer/salt-IL ATPS, the strategy 
herein adopted with ILs acting as adjuvants employ lower concentrations of ILs, thus 
contributing to more amenable and less expensive strategies.
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4. CONCLUSIONS:
The purification of IFNα-2b as a major protein biopharmaceutical using polymer-
polymer ATPS and ILs as adjuvants was attempted in this work. The IFNα-2b upstream 
stage consisted of E. coli BL21 (DE3) cultivation with the target protein accumulated as 
inclusion bodies, followed by E. coli lysis with glass beads and inclusion bodies 
solubilization with a buffer containing urea and at alkaline pH. After the phase diagrams 
determination, ATPS were then investigated for IFNα-2b purification by enriching IFNα-
2b in the PEG-rich phase, with the simultaneous precipitation of the remaining proteins 
at the interface (fitting within the three-phase partitioning approach). Overall, ILs present 
in higher quantities in the PEG-rich phase, being those composed of aromatic cations and 
anions with high hydrogen-bond basicity, allow to obtain higher IFNα-2b purification 
factors. Accordingly, electrostatic, π-‧‧‧π and hydrogen-bond interactions seem to be the 
main forces ruling the target protein selective partitioning to the PEG-rich phase, where 
ILs are preferentially partitioned. The IFNα-2b recovered in the bottom PEG-rich phase 
was shown to be immunologically active, with its secondary structure preserved. In 
summary, this work reinforces the potential effect brought by the use of ILs in small 
concentrations as adjuvants in PEG-PPG ATPS, by enhancing the purity of high-value 
proteins such as IFNα-2b. 
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6. FIGURES LEGENDS:
Fig. 1 - Phase diagrams at 25 (± 1) °C and atmospheric pressure for systems composed of 
PPG 400, PEG 600 and 10 mM Tris pH 8 in the absence and presence of 5 wt% of the 
following ILs as adjuvants: [C4mim]Cl; [C4mim]Br; [C4mim][CH3COO]; [C2mim]Cl; 
[C6mim]Cl; [Ch]Cl; [N4444]Cl. Phase diagrams were organized according to the chemical 
structure of IL, namely according to the type of IL cation, the type of IL anion and the 
impact of the length of the alkyl side chain, respectively, A, B, and C.
Fig. 2 - SDS-PAGE and western-blot analysis of fractions obtained during the 
solubilization of inclusion bodies from recombinant E. coli BL21 (DE3) harboring pET-
3a_ IFNα-2b.
Fig. 3 - SDS-PAGE analysis of representative bottom phases from ATPS composed of 
PEG 600 at 30 wt% + PPG 400 at 30 wt% in the presence and absence of 5 wt% of IL.
Fig. 4 - Purification factors (blue bars) and extraction efficiencies (black dots) of IFNα-
2b recovered in the bottom phase of ATPS composed of 30 wt% of PEG 600 and 30 wt% 
of PPG 400 in the absence and presence of 5 wt% of ILs. 
Fig. 5 - Western blot analysis of the phases of representative ATPS (30 wt% of PEG 600 
and 30 wt% of PPG 400) investigated in the absence (A) and presence of 5 wt% of 
[C4mim][CH3COO] (B). A commercial IFNα-2b standard is included for comparison.
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HIGHLIGHTS:
1. IFNα-2b purification improvements are achieved using polymer-polymer ATPS with 
ILs as adjuvants.
2. The biphasic region of investigated ATPS can be tailored with the ionic liquid chemical 
structure.
3. IFNα-2b is mainly enriched in the PEG-rich phase, whereas the remaining proteins 
tend to precipitate at the ATPS interface.
4. ILs with aromatic cations and anions with high hydrogen-bond basicity enhance the 
IFNα-2b purity.
5. The stability and immunological activity of IFNα-2b is preserved during purification.
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